Oscar Health, Inc.
$24.73-$1.44 (-5.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $7.1B
- P/E
- -16.1x
- Revenue
- $11.7B
- Net margin
- -3.8%
- ROCE
- -29.8%
Price chart
Technical chartScreen technicals →+89.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -26.5%
- 3M
- -21.7%
- 6M
- +5.6%
- 1Y
- +89.8%
- 5Y
- +140.1%
52-week range
Day change -$1.44 (-5.5%) from $26 to $25 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in OSCR, bought on each weekday since 2021.
News & filings
What Oscar Health filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 443 million US dollars in fiscal 2025.
Strengths (1)
- Revenue grew 41.6% a year over three years.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products.
Read moreShow less
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
- Sector
- Healthcare
- Shares outstanding
- 297.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $7.1B
- P/E
- -16.1x
- P/B
- 7.3x
- EV / Sales
- 0.4x
- P/S
- 0.6x
- 52-week high
- $35.19
- 52-week low
- $10.85
Profitability
- Operating margin
- -3.6%
- Net margin
- -3.8%
- ROE
- -45.3%
- ROCE
- -29.8%
- ROA
- -7.0%
- Asset turnover
- 1.85
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $11.7B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 27.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 41.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1842.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $1.1B
Solvency
- Debt / Equity
- 0.44
- Debt / Assets
- 0.07
- CFO / Net profit
- -2.47
- Cash / Market cap
- 39.0%
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Revenue | $11.7B |
| Gross profit | $11.7B |
| Operating expenses | — |
| Selling, general and administrative | $2.0B |
| Pretax income | -$437.3M |
| Tax and other | $5.8M |
| Net income | -$443.1M |
Revenue and net profit
Revenue grew 27.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $4.1B | -$606.3M |
| FY2023 | $5.9B | -$270.7M |
| FY2024 | $9.2B | $25.4M |
| FY2025 | $11.7B | -$443.2M |
Cash flows
FY2025: $1.1B from operations, $1.1B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $380.3M | $351.3M |
| FY2023 | -$272.2M | -$297.7M |
| FY2024 | $978.2M | $950.3M |
| FY2025 | $1.1B | $1.1B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $11.7B+27.5%1Y
- Net profit
- -$443.2M-1,842.5%1Y
- Cash from operations
- $1.1B+11.9%1Y
- Free cash flow
- $1.1B+11.4%1Y
- Revenue CAGR, 3Y
- 41.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $11.7B | — | -$443.2M | $1.1B | -45.3% | +27.5% | -1842.5% |
Monthly returns
Month-by-month returns of OSCR across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $6.3B |
| Current assets | — |
| Non-current assets | — |
| Liabilities | $5.3B |
| Current liabilities | — |
| Non-current liabilities | — |
| Equity | $980.7M |
| Paid-in capital | $4.3B |
| Retained earnings | -$3.3B |
| Treasury stock | $2.9M |
| Minority interest | $3.1M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; OSCR highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc., Praxis Precision Medicines, Inc., Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Immunovant, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Oscar Health, Inc.OSCRthis company | $7.1B | -16.1x | 7.3x | -45.3% | — |
| Nuvalent, Inc.NUVL | $7.4B | -17.5x | 5.9x | -34.1% | — |
| Praxis Precision Medicines, Inc.PRAX | $7.4B | -24.3x | 8.4x | -34.5% | -21.5x |
| HealthEquity, Inc.HQY | $7.2B | 33.4x | 3.4x | 10.2% | 16.1x |
| Vaxcyte, Inc.PCVX | $7.0B | -9.2x | 2.6x | -28.5% | -7.8x |
| Apogee Therapeutics, Inc.APGE | $6.9B | -26.8x | 7.6x | -28.3% | -23.7x |
| Spyre Therapeutics, Inc.SYRE | $6.8B | — | 9.5x | -21.7% | — |
| Arcellx, Inc.ACLX | $6.7B | -29.4x | 16.7x | -56.9% | -30.2x |
| Immunovant, Inc.IMVT | $6.7B | -13.3x | 7.9x | -59.3% | -10.9x |
| Peer median | — | -17.5x | 7.7x | -31.3% | -16.2x |
Year-to-date ROI
OSCR since 1 January, against earlier years.
Historical volatility
OSCR's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $11.7B |
| Operating expenses | |
| Selling, general and administrativeSelling General And Administration | $2.0B |
| Other operating expensesOther Operating Expenses | $23.3M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $28.9M |
| Total expensesTotal Expenses | $12.1B |
| Interest and other | |
| Pretax incomePretax Income | -$437.3M |
| TaxTax Provision | $5.6M |
| Net incomeNet Income | -$443.1M |
| Per share | |
| Supplementary | |
| Other lines |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $6.3B |
| Current assets | |
| Non-current assets | |
| LiabilitiesTotal Liabilities Net Minority Interest | $5.3B |
| Current liabilities | |
| Non-current liabilities | |
| EquityTotal Equity Gross Minority Interest | $980.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $1.1B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $1.1B |
| Net income, continuing operationsNet Income From Continuing Operations | -$442.9M |
| Depreciation and amortisationDepreciation And Amortization | $28.9M |
| Amortization of securitiesAmortization Of Securities | -$29.8M |
| Stock-based compensationStock Based Compensation | $87.7M |
| Deferred taxDeferred Tax | $2.5M |
| Deferred income taxDeferred Income Tax | $2.5M |
| Operating gains and lossesOperating Gains Losses | -$1.3M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$1.3M |
| Change in working capitalChange In Working Capital | $1.5B |
| Other non-cash itemsOther Non Cash Items | -$10.7M |
| Investing cash flowInvesting Cash Flow | -$241.1M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$241.1M |
| Capital expenditureCapital Expenditure | -$36.4M |
| Purchase of PP&EPurchase Of PPE | -$36.4M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$36.4M |
| Purchase of investmentsPurchase Of Investment | -$1.0B |
| Sale of investmentsSale Of Investment | $805.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$209.0M |
| Other investing changesNet Other Investing Changes | $4.3M |
| Financing cash flowFinancing Cash Flow | $399.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $399.2M |
| Debt issuedIssuance Of Debt | $410.0M |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | $410.0M |
| Long-term debt issuedLong Term Debt Issuance | $410.0M |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | $410.0M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | $55.0M |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | -$65.8M |
| Change in cashChanges In Cash | $1.3B |
| Cash at the start of the yearBeginning Cash Position | $1.6B |
| Cash at the end of the yearEnd Cash Position | $2.8B |
| Free cash flowFree Cash Flow | $1.1B |
| Supplemental |
Learn while you research
Academy chapters picked for Oscar Health, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing27% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read